Literature DB >> 23775075

Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.

Cullen L Schmid1, John M Streicher, Chad E Groer, Thomas A Munro, Lei Zhou, Laura M Bohn.   

Abstract

There is considerable evidence to suggest that drug actions at the κ-opioid receptor (KOR) may represent a means to control pain perception and modulate reward thresholds. As a G protein-coupled receptor (GPCR), the activation of KOR promotes Gαi/o protein coupling and the recruitment of β-arrestins. It has become increasingly evident that GPCRs can transduce signals that originate independently via G protein pathways and β-arrestin pathways; the ligand-dependent bifurcation of such signaling is referred to as "functional selectivity" or "signaling bias." Recently, a KOR agonist, 6'-guanidinonaltrindole (6'-GNTI), was shown to display bias toward the activation of G protein-mediated signaling over β-arrestin2 recruitment. Therefore, we investigated whether such ligand bias was preserved in striatal neurons. Although the reference KOR agonist U69,593 induces the phosphorylation of ERK1/2 and Akt, 6'-GNTI only activates the Akt pathway in striatal neurons. Using pharmacological tools and β-arrestin2 knock-out mice, we show that KOR-mediated ERK1/2 phosphorylation in striatal neurons requires β-arrestin2, whereas Akt activation depends upon G protein signaling. These findings reveal a point of KOR signal bifurcation that can be observed in an endogenous neuronal setting and may prove to be an important indicator when developing biased agonists at the KOR.

Entities:  

Keywords:  Arrestin; Brain; Drug Screening; G Protein-coupled Receptors (GPCR); Gene Knockout; MAP Kinases (MAPKs); Neurons; Opiate Opioid; Receptor Endocytosis; κ-Opioid Receptor

Mesh:

Substances:

Year:  2013        PMID: 23775075      PMCID: PMC3829329          DOI: 10.1074/jbc.M113.476234

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo.

Authors:  Cullen L Schmid; Laura M Bohn
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

2.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

Authors:  Maria Waldhoer; Jamie Fong; Robert M Jones; Mary M Lunzer; Shiv K Sharma; Evi Kostenis; Philip S Portoghese; Jennifer L Whistler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

Review 3.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

4.  A simple method for quantifying functional selectivity and agonist bias.

Authors:  Terry Kenakin; Christian Watson; Vanessa Muniz-Medina; Arthur Christopoulos; Steven Novick
Journal:  ACS Chem Neurosci       Date:  2011-12-20       Impact factor: 4.418

5.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

6.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

7.  An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

Authors:  C E Groer; K Tidgewell; R A Moyer; W W Harding; R B Rothman; T E Prisinzano; L M Bohn
Journal:  Mol Pharmacol       Date:  2006-11-07       Impact factor: 4.436

8.  Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity.

Authors:  Ashlee Van't Veer; Anita J Bechtholt; Sara Onvani; David Potter; Yujun Wang; Lee-Yuan Liu-Chen; Günther Schütz; Elena H Chartoff; Uwe Rudolph; Bruce M Cohen; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2013-02-27       Impact factor: 7.853

9.  Buprenorphine treatment of refractory depression.

Authors:  J A Bodkin; G L Zornberg; S E Lukas; J O Cole
Journal:  J Clin Psychopharmacol       Date:  1995-02       Impact factor: 3.153

10.  Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.

Authors:  Benjamin B Land; Michael R Bruchas; Selena Schattauer; William J Giardino; Megumi Aita; Daniel Messinger; Thomas S Hnasko; Richard D Palmiter; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-28       Impact factor: 11.205

View more
  48 in total

Review 1.  Functional selectivity of GPCR signaling in animals.

Authors:  Lei Zhou; Laura M Bohn
Journal:  Curr Opin Cell Biol       Date:  2013-12-22       Impact factor: 8.382

2.  Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.

Authors:  Selena S Schattauer; Jamie R Kuhar; Allisa Song; Charles Chavkin
Journal:  Cell Signal       Date:  2017-01-11       Impact factor: 4.315

3.  Synthesis of Kappa Opioid Antagonists Based On Pyrrolo[1,2-α]quinoxalinones Using an N-Arylation/Condensation/Oxidation Reaction Sequence.

Authors:  Sarah M Scarry; Kimberly M Lovell; Kevin J Frankowski; Laura M Bohn; Jeffrey Aubé
Journal:  J Org Chem       Date:  2016-08-02       Impact factor: 4.354

4.  Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.

Authors:  Jenny Morgenweck; Kevin J Frankowski; Thomas E Prisinzano; Jeffrey Aubé; Laura M Bohn
Journal:  Neuropharmacology       Date:  2015-08-25       Impact factor: 5.250

5.  A novel method for analyzing extremely biased agonism at G protein-coupled receptors.

Authors:  Edward L Stahl; Lei Zhou; Frederick J Ehlert; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-02-13       Impact factor: 4.436

Review 6.  Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Authors:  Louis M Luttrell; Stuart Maudsley; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

7.  Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons.

Authors:  Blaine A Jacobs; Miryam M Pando; Elaine M Jennings; Raehannah J Jamshidi; Joshua C Zamora; Teresa S Chavera; William P Clarke; Kelly A Berg
Journal:  Neuropharmacology       Date:  2019-02-15       Impact factor: 5.250

Review 8.  The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.

Authors:  Yuri K Peterson; Louis M Luttrell
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

Review 9.  The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.

Authors:  Matthew L Banks
Journal:  Handb Exp Pharmacol       Date:  2020

10.  Identification of novel functionally selective κ-opioid receptor scaffolds.

Authors:  Kate L White; Alex P Scopton; Marie-Laure Rives; Ruslan V Bikbulatov; Prabhakar R Polepally; Peter J Brown; Terrance Kenakin; Jonathan A Javitch; Jordan K Zjawiony; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.